GRTS | Gritstone Oncology

Company profile

Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The lead product candidate, GRANITE, is a personalized neoantigen-based immunotherapy. The second product candidate, SLATE, is a shared neoantigen (?off-the-shelf?) immunotherapy. The company has developed its product candidates using two key pillars?a proprietary machine learning-based platform, Gritstone EDGE?, which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient's tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients' TSNA to drive the patient's immune system to attack and destroy tumors.